ARA: Equity ResearchTwo closings in one quarter (Q1/06) and multiple institutional investors (new and old) says quite a lot. There
seems to be recognition by the asset managers to the future but can/will the retail investors follow?
Reiterating, SoftScan® has been developed for the detection and treatment monitoring of breast cancer. It is
expected to be used if results of a mammography are suspicious or inconclusive, and then for monitoring of breast
cancer (adjunctive and complementary to diagnostic mammography). The system may also more accurately diagnose
premenopausal women with dense breast tissue, where mammography tends to be less precise. The small
percentage of breast cancers without symptoms that are not identified by mammography (10% to 20%) may be
missed because of breast density, faster tumor growth rate or human error in recognizing early signs of an
abnormality. About 5% to 10% of women have their mammograms interpreted as abnormal or inconclusive until
further tests are done¹. Currently, a suspicious mammogram is generally followed by a biopsy, even though 80% of
cases prove to be negative². ARA.TO’s SoftScan® may be able to reduce the number of painful biopsies and better
diagnose and monitor breast cancer. ARA.TO plans on filing for regulatory approval (Q2-3/06) with the FDA,
Health Canada, and the European Union (CE mark) but it does take 3-6 months for the review process and
determination. SoftScan® initial preclinical trial results were published in August 2005 and were positive.